Neonc Technologies Holdings Inc (NTHI)

$12.00 -0.11 (-0.91%)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 9,700
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trials for the treatment of glioblastoma; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration to patients with primary and s...

Industry: Biotechnology
Sector: Healthcare
Phone: 310-663-7831
Address:
23975 Park Sorrento, Suite 205, Calabasas, United States
NeOnc_Technologies
NeOnc_Technologies Nov. 6 at 9:50 AM
$NTHI NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Directors, ensuring his continued leadership over NeOnc's innovative scientific strategy and clinical development. https://www.globenewswire.com/news-release/2025/11/04/3180411/0/en/NeOnc-Technologies-Appoints-Amir-Heshmatpour-as-Chief-Executive-Officer-to-Drive-Next-Phase-of-Clinical-and-Corporate-Growth.html
0 · Reply
U_rappoport
U_rappoport Nov. 5 at 2:39 PM
$NTHI this level of transparency 🙌
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 5 at 12:52 PM
$NTHI At NeOnc Technologies, our world-class leadership team unites scientific innovation with strategic vision to transform brain and central nervous system therapeutics. Led by Executive Chairman Amir Heshmatpour and Founder & CEO Dr. Thomas Chen, alongside CFO Keithly A. Garnett and Chief Clinical Officer Dr. Josh Neman, our leaders bring deep expertise in science, medicine, and business. Guided by a distinguished Board and Scientific Advisory Board, including leading clinicians and researchers such as Dr. David Ashley, Dr. Henry Friedman, and Dr. Steven Giannotta, we are pioneering new standards of care for patients worldwide. Our mission is clear: advance groundbreaking therapies, deliver meaningful patient outcomes, and create lasting value for all stakeholders.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 4 at 1:31 PM
$NTHI October has been an exciting month for NeOnc Technologies, marked by three significant announcements: • NuroMENA Signs Master Services Agreement with M42’s IROS and Expands Board of Directors: Our subsidiary, NuroMENA, strengthened its strategic footprint through this agreement, positioning us for accelerated growth and innovation. • His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies’ Subsidiary: Strengthening UAE-US collaboration to advance breakthrough brain cancer treatment. • Appointment of Dr. David M. Ashley to Scientific Advisory Board: Dr. Ashley, Director of the Preston Robert Tisch Brain Tumor Center at Duke, joined our Scientific Advisory Board, bringing unparalleled expertise in neuro-oncology research and clinical practice. • Appointment of Dr. Alexandra M. Miller to Scientific Advisory Board: Dr. Miller joined our Scientific Advisory Board, further strengthening our leadership in cutting-edge brain tumor research.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 30 at 8:50 AM
$NTHI His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment This historic support marks the direct involvement in leading a biotechnology venture focused on developing breakthrough treatments for brain cancer and other central nervous system malignancies. https://investors.neonc.com/news-releases/news-release-details/his-highness-sheikh-nahyan-bin-zayed-al-nahyan-assumes-executive
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 22 at 8:54 AM
$NTHI Seeking Alpha Analyst Valuing $NTHI Following Recent $50M Quazer Deal “During my research, something big happened. The $50 million Quazar partnership is about to close. It looked like my rating was leaning towards a "hold," but this changes things. Now that the final government approvals in the UAE are done and the deal is expected to close by October 23, NeOnc is moving from 'potential funding' to real money in the bank.” - Said Grassroots Training, Seeking Alpha Analyst
1 · Reply
NeOncResponder
NeOncResponder Oct. 21 at 11:08 AM
$NTHI | Official Responder Launch 🚀 Welcome to the official NeOnc Technologies ($NTHI) Responder account! This profile is managed in coordination with the NeOnc team to ensure accurate, timely, and transparent communication with our shareholders. Through this channel, we’ll: • Answer shareholder questions with factual responses. • Clarify public information and company updates. • Address misinformation circulating online. • Help investors better understand our progress and vision. Our mission is to make engagement between NeOnc Technologies and the investment community more open, informed, and accessible. 💬 Have a question about $NTHI or our ongoing programs? Ask us here, our team is listening and ready to respond.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 16 at 2:07 PM
$NTHI After 18 months of dedication and collaboration, NeOnc Technologies (NASDAQ: NTHI), together with Quazar Investment, M42/IROS, and Norton Rose Fulbright, has launched NuroMENA. This milestone underscores NeOnc’s commitment to advancing innovative CNS therapies and aims to transform care for patients and families facing brain cancer and other CNS diseases across the GCC and MENA region.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 15 at 9:46 AM
$NTHI “Signing an agreement with IROS, an entity backed by a global force like M42, is a transformative event,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “This MSA provides the elite infrastructure needed to fast-track our clinical trials. By simultaneously installing a powerful board with our partners at Quazar, we are establishing a premier foundation for both operational excellence and strategic leadership in the Middle East. Together, these actions will dramatically accelerate our mission to bring novel cancer treatments to patients.” https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-subsidiary-nuromena-signs-master-services
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 13 at 8:51 AM
$NTHI NeOnc Technologies’ Subsidiary NuroMENA Signs Key Partnership and Expands Board, Announcing Two Strategic Developments: • Master Services Agreement with IROS: Partnering with the UAE-based CRO to accelerate clinical development of NeOnc’s CNS cancer therapies. • Board Expansion: Welcoming Waleed K. Al Ali to strengthen regional leadership and growth. These steps position NeOnc to advance its innovative therapies while building a hub for clinical excellence in Abu Dhabi. https://www.sec.gov/Archives/edgar/data/1979414/000182912625008052/neonctechnologies_8k.htm
1 · Reply
Latest News on NTHI
NeOnc Technologies: From Survival Mode To Expansion Mode

Oct 9, 2025, 2:25 PM EDT - 4 weeks ago

NeOnc Technologies: From Survival Mode To Expansion Mode

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

Oct 9, 2025, 9:00 AM EDT - 4 weeks ago

NeOnc Technologies' Subsidiary, NuroMENA, Signs Master Services Agreement with M42's IROS and Expands Board of Directors

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Sep 29, 2025, 9:00 AM EDT - 5 weeks ago

NeOnc Technologies Appoints Renowned Neuro-Oncologist Dr. Henry S. Friedman to Scientific Advisory Board

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

Sep 10, 2025, 9:40 AM EDT - 2 months ago

Blue Gold Appoints Quazar's Sameer Salgar to Advisory Board to Establish UAE Ties and Guide Digital Gold Strategy

BGL

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

Sep 10, 2025, 9:00 AM EDT - 2 months ago

NeOnc Technologies Receives FDA Authorization to Proceed with Phase II Clinical Trial of NEO212 – A First-in-Class Oral Chemical Conjugated Chemotherapy Candidate for Brain Cancer

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

Aug 25, 2025, 9:00 AM EDT - 2 months ago

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Aug 11, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

Aug 7, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

Aug 4, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

Jul 30, 2025, 9:00 AM EDT - 3 months ago

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

Jul 23, 2025, 10:53 AM EDT - 3 months ago

CORRECTING and REPLACING - NeOnc Technologies Holdings, Inc.

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

Jul 8, 2025, 9:00 AM EDT - 4 months ago

NeOnc Technologies Signs $50 Million Non-Binding Strategic Term Sheet with Quazar Investment to Launch GCC & MENA Expansion and Clinical Trials Platform

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

Jun 6, 2025, 9:00 AM EDT - 5 months ago

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

Apr 15, 2025, 8:05 AM EDT - 7 months ago

NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

Apr 14, 2025, 8:05 AM EDT - 7 months ago

NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

Apr 10, 2025, 8:05 AM EDT - 7 months ago

NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

Apr 8, 2025, 4:05 PM EDT - 7 months ago

NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

Mar 31, 2025, 8:05 AM EDT - 7 months ago

NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

Mar 27, 2025, 8:05 AM EDT - 8 months ago

NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

Mar 25, 2025, 8:45 AM EDT - 8 months ago

NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

Mar 25, 2025, 8:15 AM EDT - 8 months ago

NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

Jan 4, 2025, 12:30 AM EST - 10 months ago

U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings

AERO CAPS CRGT FBGL FLOC INLF INR

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

Oct 7, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

Aug 5, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Begins Enrollment for Phase 2 Clinical Trial of NEO100-02™ for Patients Afflicted with Meningioma, Marking Second Concurrent Phase 2 Study of Leading CNS Cancer Drug Candidate

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

Jul 16, 2024, 11:15 AM EDT - 1 year ago

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

Jun 26, 2024, 4:39 PM EDT - 1 year ago

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

May 15, 2024, 11:00 AM EDT - 1 year ago

NeOnc Technologies Wins California Investment Forum's Breakthrough Medical Technology Achievement Award

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

May 9, 2024, 5:30 PM EDT - 1 year ago

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

Mar 30, 2024, 1:00 AM EDT - 1 year ago

U.S. IPO Weekly Recap: Biotech Leads Short 3 IPO Week

BOLD MMA MNDR NTCL ROTR UBXG WAY

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

Dec 25, 2023, 9:05 AM EST - 2 years ago

U.S. IPO Weekly Recap: Small Japanese Lists In The US As Insurer Aspen Holdings Joins The IPO Pipeline

LGCB MAMO LZMH

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

Dec 20, 2023, 2:38 PM EST - 2 years ago

Neonc Technologies Seeks U.S. IPO For Brain Cancer Treatment Pipeline

NeOnc_Technologies
NeOnc_Technologies Nov. 6 at 9:50 AM
$NTHI NeOnc Technologies Appoints Amir Heshmatpour as Chief Executive Officer to Drive Next Phase of Clinical and Corporate Growth Dr. Thomas Chen, the company's founder, will transition from the CEO role to focus exclusively on his positions as Chief Medical Officer, Chief Scientific Officer, and member of the Board of Directors, ensuring his continued leadership over NeOnc's innovative scientific strategy and clinical development. https://www.globenewswire.com/news-release/2025/11/04/3180411/0/en/NeOnc-Technologies-Appoints-Amir-Heshmatpour-as-Chief-Executive-Officer-to-Drive-Next-Phase-of-Clinical-and-Corporate-Growth.html
0 · Reply
U_rappoport
U_rappoport Nov. 5 at 2:39 PM
$NTHI this level of transparency 🙌
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 5 at 12:52 PM
$NTHI At NeOnc Technologies, our world-class leadership team unites scientific innovation with strategic vision to transform brain and central nervous system therapeutics. Led by Executive Chairman Amir Heshmatpour and Founder & CEO Dr. Thomas Chen, alongside CFO Keithly A. Garnett and Chief Clinical Officer Dr. Josh Neman, our leaders bring deep expertise in science, medicine, and business. Guided by a distinguished Board and Scientific Advisory Board, including leading clinicians and researchers such as Dr. David Ashley, Dr. Henry Friedman, and Dr. Steven Giannotta, we are pioneering new standards of care for patients worldwide. Our mission is clear: advance groundbreaking therapies, deliver meaningful patient outcomes, and create lasting value for all stakeholders.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Nov. 4 at 1:31 PM
$NTHI October has been an exciting month for NeOnc Technologies, marked by three significant announcements: • NuroMENA Signs Master Services Agreement with M42’s IROS and Expands Board of Directors: Our subsidiary, NuroMENA, strengthened its strategic footprint through this agreement, positioning us for accelerated growth and innovation. • His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies’ Subsidiary: Strengthening UAE-US collaboration to advance breakthrough brain cancer treatment. • Appointment of Dr. David M. Ashley to Scientific Advisory Board: Dr. Ashley, Director of the Preston Robert Tisch Brain Tumor Center at Duke, joined our Scientific Advisory Board, bringing unparalleled expertise in neuro-oncology research and clinical practice. • Appointment of Dr. Alexandra M. Miller to Scientific Advisory Board: Dr. Miller joined our Scientific Advisory Board, further strengthening our leadership in cutting-edge brain tumor research.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 30 at 8:50 AM
$NTHI His Highness Sheikh Nahyan bin Zayed Al Nahyan Assumes Executive Chairmanship of NeOnc Technologies' Subsidiary, NuroMENA, Pioneering UAE-US Partnership in Brain Cancer Treatment This historic support marks the direct involvement in leading a biotechnology venture focused on developing breakthrough treatments for brain cancer and other central nervous system malignancies. https://investors.neonc.com/news-releases/news-release-details/his-highness-sheikh-nahyan-bin-zayed-al-nahyan-assumes-executive
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 22 at 8:54 AM
$NTHI Seeking Alpha Analyst Valuing $NTHI Following Recent $50M Quazer Deal “During my research, something big happened. The $50 million Quazar partnership is about to close. It looked like my rating was leaning towards a "hold," but this changes things. Now that the final government approvals in the UAE are done and the deal is expected to close by October 23, NeOnc is moving from 'potential funding' to real money in the bank.” - Said Grassroots Training, Seeking Alpha Analyst
1 · Reply
NeOncResponder
NeOncResponder Oct. 21 at 11:08 AM
$NTHI | Official Responder Launch 🚀 Welcome to the official NeOnc Technologies ($NTHI) Responder account! This profile is managed in coordination with the NeOnc team to ensure accurate, timely, and transparent communication with our shareholders. Through this channel, we’ll: • Answer shareholder questions with factual responses. • Clarify public information and company updates. • Address misinformation circulating online. • Help investors better understand our progress and vision. Our mission is to make engagement between NeOnc Technologies and the investment community more open, informed, and accessible. 💬 Have a question about $NTHI or our ongoing programs? Ask us here, our team is listening and ready to respond.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 16 at 2:07 PM
$NTHI After 18 months of dedication and collaboration, NeOnc Technologies (NASDAQ: NTHI), together with Quazar Investment, M42/IROS, and Norton Rose Fulbright, has launched NuroMENA. This milestone underscores NeOnc’s commitment to advancing innovative CNS therapies and aims to transform care for patients and families facing brain cancer and other CNS diseases across the GCC and MENA region.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 15 at 9:46 AM
$NTHI “Signing an agreement with IROS, an entity backed by a global force like M42, is a transformative event,” said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies. “This MSA provides the elite infrastructure needed to fast-track our clinical trials. By simultaneously installing a powerful board with our partners at Quazar, we are establishing a premier foundation for both operational excellence and strategic leadership in the Middle East. Together, these actions will dramatically accelerate our mission to bring novel cancer treatments to patients.” https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-subsidiary-nuromena-signs-master-services
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 13 at 8:51 AM
$NTHI NeOnc Technologies’ Subsidiary NuroMENA Signs Key Partnership and Expands Board, Announcing Two Strategic Developments: • Master Services Agreement with IROS: Partnering with the UAE-based CRO to accelerate clinical development of NeOnc’s CNS cancer therapies. • Board Expansion: Welcoming Waleed K. Al Ali to strengthen regional leadership and growth. These steps position NeOnc to advance its innovative therapies while building a hub for clinical excellence in Abu Dhabi. https://www.sec.gov/Archives/edgar/data/1979414/000182912625008052/neonctechnologies_8k.htm
1 · Reply
martinfpl86
martinfpl86 Oct. 8 at 6:14 PM
$NTHI Ok, $NTHI is starting to get interesting again. Been holding a small position since summer and adding dips. Brain cancer drug pipeline is always a tough field but they’ve actually got data + partnerships that make this one different. I like how they’re focused on delivery systems for hard-to-treat tumors. that’s a legit edge. Super low market cap and any hint of progress on trials could move this fast. I’m in for the science. + this UAE deal is very interesting.
1 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 8 at 4:58 PM
$NTHI "This transaction represents a pivotal milestone, empowering us to initiate ALL FOUR of our upcoming clinical trials: NEO100-01 and NEO100-02, as well as NEO212, all advancing into Phase 2a/2b, and NEO100-03, our first pediatric brain cancer program entering Phase 1." Said Amir Heshmatpour, Executive Chairman and President of NeOnc Technologies.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 6 at 4:26 PM
$NTHI NeOnc Technologies and Quazar Investment Set to Close $50 Million Strategic Partnership by October 23rd, Following Final UAE Tax Approvals • $50M strategic partnership with Quazar Investment mandated to close no later than October 23, 2025, following final UAE regulatory approvals. • Partnership centered on NuroCure, NeOnc’s Abu Dhabi subsidiary under NuroMENA Holdings Ltd., to drive trials and infrastructure across the UAE and MENA region. • $15M of the funding allocated to Phase 2B clinical trials and UAE infrastructure development. • Enables initiation of four clinical programs — NEO100-01, NEO100-02, NEO212 (Phase 2a/2b), and NEO100-03, the company’s first pediatric Phase 1 trial. • Supported by an expanded Scientific Advisory Board (Drs. Friedman, Miller, Ashley, Chen) and collaboration with the Cleveland Clinic Abu Dhabi to advance CNS cancer care globally. https://finance.yahoo.com/news/neonc-technologies-quazar-investment-set-130000126.html
0 · Reply
FlashCrashHero
FlashCrashHero Oct. 5 at 2:24 PM
$NTHI Technology services micro-cap. No pattern recognition. Illiquid conditions. Avoid.
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 1 at 9:58 PM
$NTHI NeOnc Technologies Welcomes Dr. Alexandra M. Miller, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at NYU Langone Health’s Perlmutter Cancer Center, to Its Scientific Advisory Board https://investors.neonc.com/news-releases/news-release-details/neonc-technologies-welcomes-dr-alexandra-m-miller-chief-neuro
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Oct. 1 at 3:02 PM
$NTHI Following FDA authorization to advance its Phase II clinical trial of NEO212, NeOnc Technologies will expand patient enrollment at leading U.S. cancer centers, adding to the four sites already approved and active. - NextGen Oncology – Kumar Sankhala, MD - Northwest Medical Specialties (NWMS) – Jorge Chaves, MD - Oncology Physician’s Network – Vu Phan, MD - University of Southern California (USC) – Frances Chow, MD
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Sep. 30 at 7:14 PM
$NTHI 🎙️ NeOnc Technologies ($NTHI) Featured on Trader Talk with Kenny Polcari Amir Heshmatpour, Executive Chairman & President of NeOnc Technologies, recently joined renowned market commentator Kenny Polcari on Trader Talk. The discussion highlighted NeOnc’s progress as an emerging small-cap biotech and its global strategy to advance cancer treatment through innovative drug delivery methods. 📺 Watch the full interview here: https://finance.yahoo.com/video/ai-biotech-brain-cancer-100043492.html
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Sep. 29 at 7:32 PM
$NTHI NeOnc Technologies has appointed Dr. Henry S. Friedman to its scientific advisory board. Dr. Friedman is an internationally renowned academic adult and pediatric neuro-oncologist who helps to lead The Preston Robert Tisch Brain Tumor Center at Duke University. He is the author of more than 500 peer reviewed articles, reviews, and book chapters and has presented extensively at both international and national meetings. https://finance.yahoo.com/news/neonc-technologies-receives-fda-approval-134821003.html
0 · Reply
NeOnc_Technologies
NeOnc_Technologies Sep. 29 at 7:31 PM
$NTHI Welcome to the official NeOnc Technologies Investor Relations profile. Here you’ll find the latest news, financial updates, and official company announcements. We’re committed to keeping our shareholders informed, engaged, and confident in our vision.
0 · Reply
Estebanvel
Estebanvel Sep. 25 at 7:21 PM
$NTHI 10th October is coming....
0 · Reply
intratio
intratio Sep. 21 at 5:03 PM
The model is making the inference the value of this equity will immediately and drastically decrease and foretells a grimly dismal future $NTHI
2 · Reply
StockScanners
StockScanners Sep. 14 at 1:01 AM
$NTHI reached 10.92
1 · Reply